Dublin, Ireland, Oct. 20, 2021 (GLOBE NEWSWIRE) – STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it will host a conference call to discuss its financial results from second quarter of fiscal 2022 at 10 am ET on November 3, 2021. The conference call can be streamed live at www.steris-ir.com or by phone by dialing 1-833-535-2199 in the US or international 1-412-902-6776, then requesting to join the conference call for STERIS plc.
A press release detailing the second quarter financial results will be released after the U.S. market closes on November 2, 2021.
For those unable to listen to the live conference call, a replay will be available starting at 12:00 p.m. ET on November 3, 2021, either at www.steris-ir.com or by phone. To access the replay of the call, please use access code 10160982 and dial 1-877-344-7529 in the US or 1-412-317-0088 internationally.
STERIS is one of the world’s leading providers of products and services that support patient care with a focus on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND MORE SR WORLD by providing innovative healthcare, life science and dental care products and services. For more information, visit www.steris.com.
Julie Winter, Vice-President, Investor Relations and Corporate Communications
CAUTION REGARDING FORWARD-LOOKING INFORMATION
The press release and the referenced conference call may contain statements regarding certain trends, expectations, forecasts, estimates or other forward-looking information affecting or relating to STERIS or its industry, products or activities which are intended to benefit from the protections granted “forward – forward-looking statements ”under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date on which the statement is made and can be identified by the use of forward-looking terms such as “may”, “will”, “expects”, “believes”, “anticipates”, “Forecast”, “” estimates “,” projects “,” targets “,” forecasts “,” outlook “,” impact “,” potential “,” confidence “,” improve “,” optimistic “,” deliver “,” orders “,” backlog “,” comfortable “,” trend “and” research “, or the negative of these terms or other variations on these terms or comparable terminology. Many important factors could cause actual results to occur. differ materially from those made by forward-looking statements, including, without limitation, production or supply disruptions, changes in market conditions, political events, pending or future claims or litigation, factors competitive, technological advances, the actions of regulations, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described in other STERIS securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2021. Many of these important factors are beyond our control. by STERIS. No guarantee can be given as to the outcome or timing of any outcome with respect to the matters described in the STERIS securities filings or otherwise with respect to any regulatory action, administrative proceeding, government investigation, litigation, warning letters, reductions. costs, business strategies, profits or revenue trends or future financial results. Product references are summaries only and should not be construed as specific terms of the product authorization or documentation. Except as required by law, STERIS does not undertake to update or revise forward-looking statements, even if events clearly indicate that the projected results, expressed or implied, will not be achieved. Other potential risks and uncertainties that could cause actual results to differ materially from those of forward-looking statements include, without limitation, (a) the impact of the COVID-19 pandemic on operations, performance, the results, prospects or value of STERIS, (b) the ability of STERIS to obtain the expected benefits regarding the accounting and tax treatments of redomiciliation in Ireland (“Redomiciliation”), (c) operating costs, loss of customers and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, Customers, customers or suppliers) being greater than expected as a result of Redomiciliation, (d) the ability of STERIS to successfully integrate Cantel Medical’s business into our existing business, including unknown or invaluable liabilities, or expected increases in integration costs or difficulties related to the integration of Cantel Medical (e) the ability of STERIS to meet the account expectations and tax treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility that the expected benefits resulting from the TCJA will be lower estimates, (f) changes in tax laws or interpretations that could increase our consolidated tax obligations, including changes in tax laws that would cause STERIS to be treated as a domestic company for US federal tax purposes , (g) the possibility of increased pressure on prices or costs which would lead to erosion of profit margins, (h) the possibility that market demand will not develop for new technologies, products, applications or services, or business initiatives will take longer, cost more, or produce less than expected benefits, (i) the potential for enforcement or compliance s, court decisions, certifications, regulations, actions including, without limitation, those relating to the FDA, EPA or other regulatory authorities, government investigations, the result of any pending or threatened actions d FDA, EPA or other warning notices, actions, requests, inspections or submissions, or other requirements or standards may delay, limit or prevent the introduction of new products or services, affect production, the supply and / or marketing of existing products or services or otherwise affect the performance, results, prospects or value of STERIS, (j) the potential for international unrest, economic downturn or currency effects, charges, tariffs and / or other trade barriers, anticipated adjustments or rates, raw material costs or availability, pension benefits or costs, or other regulatory compliance costs silence, (k) the possibility of reduced demand, or reductions in the rate of growth of demand, for STERIS products and services, (l) the possibility of delays in receiving orders, order cancellations, or delays in the manufacture or shipment of ordered products or in the provision of services, (m) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or d ” other outcomes may not be achieved, or that the transition, workforce, competition, schedule, execution, regulatory, government or other issues, or risks associated with the business, industry or STERIS initiatives, including, without limitation, matters described in our Annual Report on Form 10-K for the year ended March 31, 2021, and other securities filings, may have a negative impact on performance, results ats, the outlook or value of STERIS, (n) the impact on STERIS and its operations, or tax obligations, of Brexit or the exit of other EU member countries, and the Company’s ability to react to such impacts, (o) the impact on STERIS and its operations of any laws, regulations or ordinances, including, but not limited to, any new transactions or tax laws, regulations or ordinances, which may be implemented by the United States Administration or Congress, or any response thereto, (p) the possibility that the anticipated financial results or benefits of recent acquisitions, including the acquisition of Cantel Medical and Key Surgical, or STERIS restructuring efforts, or recent divestitures, including anticipated revenues, improved productivity, cost savings, growth synergies and other anticipated benefits, will not materialize. or will be other than expected, (q) the increase in the level of indebtedness of STERIS incurred in connection with the acquisition of Cantel Medical limiting financial flexibility or increasing future borrowing costs, (r) actions of rating agencies which could affect the existing debt of STERIS or its future ability to borrow funds at rates favorable to STERIS or at all, (s) the potential impact of the Cantel Medical acquisition on relationships, including with suppliers, customers, employees and regulators, and